Rapid diagnosis and characterization of acute promyelocytic leukaemia in routine laboratory practice.
Clin Lab Haematol
; 26(2): 101-6, 2004 Apr.
Article
en En
| MEDLINE
| ID: mdl-15053803
The rapid diagnosis of the t(15;17)(q22;q21) promyelocytic leukaemia is important in the early introduction of targeted therapy with all-trans retinoic acid plus chemotherapy. It has been noted that these are usually myeloperoxidase (MPO)-positive and HLA-DR-negative with homogenous expression of CD33 and heterogeneous expression of CD13. We evaluated the use of immunophenotyping, morphology and cytogenetics in our own practice. Cascade testing, using cytoplasmic MPO expression in a high percentage of blast cells in bone marrow as the primary screen and PML (promyelocytic leukaemia protein) expression as the secondary confirmatory test, allowed rapid identification of the cases with t(15;17). This approach allows early instigation of appropriate therapy.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Factores de Transcripción
/
Proteínas Nucleares
/
Antígenos de Diferenciación Mielomonocítica
/
Leucemia Promielocítica Aguda
/
Antígenos HLA-DR
/
Antígenos CD
/
Peroxidasa
/
Antígenos CD13
/
Proteínas de Neoplasias
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Adult
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Clin Lab Haematol
Año:
2004
Tipo del documento:
Article
Pais de publicación:
Reino Unido